Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 4Rhabdoid Tumor 3Pinealoma 3Neuroectodermal Tumors, Primitive 3Neoplasms, Germ Cell and Embryonal 3Multiple Myeloma 3Medulloblastoma 3Glioma 3Ependymoma 3Choroid Plexus Carcinoma 3Central Nervous System Neoplasms 3Brain Neoplasms 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Stomach Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioblastoma 1Enteropathy-Associated T-Cell Lymphoma 1Diffuse Intrinsic Pontine Glioma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

pembrolizumab 28Cisplatin 24Oxaliplatin 22Irinotecan 22Fluorouracil 22Capecitabine 20Leucovorin 17Paclitaxel 16Cyclophosphamide 14Trastuzumab 12Nivolumab 11Carboplatin 11Gemcitabine 10Bevacizumab 10Docetaxel 9fludarabine 8aldesleukin 8S 1 (combination) 8Ramucirumab 7130-nm albumin-bound paclitaxel 7atezolizumab 6Albumin-Bound Paclitaxel 6Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Biopsy 5veliparib 4tislelizumab 4spartalizumab 4dehydroftorafur 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Stomach Neoplasms × Automobiles × Clear all
NCT04650451 2023-04-20

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Bellicum Pharmaceuticals

Phase 1 Suspended
220 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡